TAVO™

Investigational Intratumoral Cancer Immunotherapy

OncoSec’s VLA: Visceral Lesion Applicator

Second Opinions, Clinical Trials & Becoming Your Own Best Advocate: Read Pat’s Story

News & Events

Designed to Arm the Immune System to Fight Cancer

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Clinical Pipeline

Our core technology platform continues to advance through clinical trials for various cancers

Learn More

Technology

Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer

Learn More

Partnerships

We have a track record of establishing, operating and evolving high-performance partnerships globally

Learn More